These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 14617570)

  • 1. Gp130-mediated signaling is necessary for normal osteoblastic function in vivo and in vitro.
    Shin HI; Divieti P; Sims NA; Kobayashi T; Miao D; Karaplis AC; Baron R; Bringhurst R; Kronenberg HM
    Endocrinology; 2004 Mar; 145(3):1376-85. PubMed ID: 14617570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
    Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC
    J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
    Lee SK; Lorenzo JA
    Endocrinology; 1999 Aug; 140(8):3552-61. PubMed ID: 10433211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D and bone.
    Suda T; Ueno Y; Fujii K; Shinki T
    J Cell Biochem; 2003 Feb; 88(2):259-66. PubMed ID: 12520524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone.
    O'Brien CA; Gubrij I; Lin SC; Saylors RL; Manolagas SC
    J Biol Chem; 1999 Jul; 274(27):19301-8. PubMed ID: 10383440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
    Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
    J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
    Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
    Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo.
    Walker EC; Poulton IJ; McGregor NE; Ho PW; Allan EH; Quach JM; Martin TJ; Sims NA
    J Bone Miner Res; 2012 Apr; 27(4):902-12. PubMed ID: 22190112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
    Kondo H; Guo J; Bringhurst FR
    J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and inhibition of osteoclast formation.
    Wang X; Wu J; Shidoji Y; Muto Y; Ohishi N; Yagi K; Ikegami S; Shinki T; Udagawa N; Suda T; Ishimi Y
    J Bone Miner Res; 2002 Jan; 17(1):91-100. PubMed ID: 11771673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development.
    Okamoto M; Murai J; Yoshikawa H; Tsumaki N
    J Bone Miner Res; 2006 Jul; 21(7):1022-33. PubMed ID: 16813523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures.
    Romas E; Udagawa N; Zhou H; Tamura T; Saito M; Taga T; Hilton DJ; Suda T; Ng KW; Martin TJ
    J Exp Med; 1996 Jun; 183(6):2581-91. PubMed ID: 8676079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone.
    Locklin RM; Khosla S; Turner RT; Riggs BL
    J Cell Biochem; 2003 May; 89(1):180-90. PubMed ID: 12682918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice.
    O'Brien CA; Jilka RL; Fu Q; Stewart S; Weinstein RS; Manolagas SC
    Am J Physiol Endocrinol Metab; 2005 Nov; 289(5):E784-93. PubMed ID: 15956054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer cells interact with osteoblasts to support osteoclast formation.
    Thomas RJ; Guise TA; Yin JJ; Elliott J; Horwood NJ; Martin TJ; Gillespie MT
    Endocrinology; 1999 Oct; 140(10):4451-8. PubMed ID: 10499498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro.
    Balga R; Wetterwald A; Portenier J; Dolder S; Mueller C; Hofstetter W
    Bone; 2006 Aug; 39(2):325-35. PubMed ID: 16580896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
    Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
    Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.